The European Association of Urology (EAU) is releasing a policy statement on live surgery ethics, prioritizing patient safety. The statement aims to establish uniform standards and monitor outcomes for EAU-approved live surgery events.
A new case series in European Urology introduces a purely intrafascial approach for robot-assisted laparoscopic prostatectomy, aiming to avoid damage to critical structures. The study reports promising results with no perioperative major complications, but highlights the need for well-designed studies to evaluate its advantages.
A new technique preserves periprostatic anatomy by keeping intact the pubovesical complex, achieving a higher rate of urinary continence after radical prostatectomy. The study reports a 25.7% weighted mean continence rate immediately after catheter removal.
European Urology has released a new impact factor of 7,667, highlighting its status as a top urological forum for over 35 years. The journal is read by 20,000 urologists globally and offers high-quality papers, fast response, and an international profile.
The REDUCE trial found dutasteride to be effective in reducing the chance of a positive biopsy by 23% and preventing disease progression. However, more detailed analyses are needed to monitor long-term effects on cardiovascular health and selectively identify aggressive disease.
A recent study by S. Eggener et al. discusses the significance and impact of focal therapy for low-risk prostate cancer patients, highlighting its potential as an alternative to whole-gland treatment. The study reviews patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for focal therapy.
The EAU Congress ended its 25th anniversary meeting in Barcelona with awards for outstanding research in urology. Despite volcanic eruptions disrupting travel plans, the congress proceeded and recognized excellence in cancer and non-cancer research.
A Phase 2 study demonstrated that BOTOX provides a clinically meaningful benefit for idiopathic OAB patients with urinary urgency incontinence. The study found that doses of 100U-150U provided the optimal balance between efficacy and safety, with significant reductions in symptoms and increases in PVR at higher doses.
The study demonstrates a potential new treatment paradigm in oncology with improved overall survival rates for metastatic castration-resistant prostate cancer patients. The treatment, Sipuleucel-T, was shown to have well-balanced prognostic factors and mild adverse events.
The EORTC 30904 study found that conservative surgery is not inferior to radical renal surgery or nephrectomy, with a slightly higher complication rate. Overall survival rates were shorter on the conservative arm for all randomized patients, but not different for RCC or clinically/pathologically eligible patients.
The European Association of Urology does not recommend mass screening for prostate cancer in Europe, citing the risk of overdiagnosis and overtreatment. Men should be properly informed by their physician about the pros and cons of screening, such as a PSA test.
The European Association of Urology Congress highlights advances in renal cell carcinoma management, including immunotherapy, targeted therapies, and angiogenesis blockers. New treatments like bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus have shown promise in stabilizing metastatic kidney cancer for a certain period.
The European Association of Urology (EAU) has launched new and updated clinical guidelines for urological conditions, including muscle-invasive and metastatic bladder cancer and prostate cancer. The guidelines provide evidence-based recommendations on diagnosis, staging, treatment options, and follow-up care.
Several urological experts were awarded prestigious medals and prizes for their groundbreaking work, including Prof. Frans Debruyne and Prof. James Catto. The awards recognized their efforts to advance urology through innovative technologies and research.
A nationwide Swedish study found no increased risk of suicide among men diagnosed with early nonpalpable prostate cancer detected by PSA testing. However, those with locally advanced or metastatic disease faced a twice-higher suicide rate compared to the general male population.
A study of 129 patients found high rates of infection and mechanical failure with inflatable prostheses; however, hydraulic devices remain the best option for achieving voiding while standing and sexual intercourse. The choice of device may favor two-piece over three-piece designs.
A systematic review found IAD to be as effective as continuous androgen deprivation while improving survival rates and sexual potency. The approach has been a valid treatment option for nonmetastatic PCa cases, offering key tolerability and quality of life benefits.
A prospective case-control survey found that male factor infertility is associated with a higher rate of medical comorbidities, as objectively scored with the Charlson Comorbidity Index. The study suggests that men with male factor infertility may be less healthy than age-comparable fertile men, regardless of their underlying causes.
A large study found that PSA velocity has little predictive value for determining the outcome of a first prostate biopsy. However, a rapid rise in PSA levels may still suggest prostatitis or prostate cancer, warranting further evaluation. The findings suggest that clinical judgment should be used to guide biopsy decisions.
The periurethral suspension technique results in significantly greater continence rates at 3 months after robot-assisted laparoscopic radical prostatectomy (RALP). The median/mean interval to recovery of continence was also statistically significantly shorter in the suspension group.
The European Association of Urology has published an evidence-based guideline for incontinent urostomy, offering expert guidance for nurses. The comprehensive 80-page document covers topics such as cystectomy, pre- and post-operative care, and community follow-up, providing best practices for managing this complex condition.
The July issue of European Urology reviews prostate cancer screening studies, highlighting the need to balance mortality reduction with overdiagnosis risks. The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening for mortality reduction.
The Prostate Cancer Translational Research in Europe meeting showcased ongoing research efforts to identify biomarkers, genetic variants and new therapeutic options. Researchers discussed the importance of collaboration between clinicians and scientists to streamline current efforts and avoid duplication.
Researchers have found that sarcosine distinguishes between slow-growing and aggressive prostate cancers. The metabolomic analysis suggests that sarcosine is highly associated with tumour development and can predict the aggressiveness of tumors.
The SPCG-4 trial found that radical prostatectomy significantly reduces prostate cancer mortality and risk of metastases, with little to no increase in benefits over a 12-year follow-up. The study suggests that well-structured pre-treatment information, patient understanding, and support are crucial for managing prostate cancer.
Researchers are developing new classes of anti-androgen therapies, including MDV3100, abiraterone, and OGX-427, to treat castrate-resistant prostate cancer (CRPC). Angiogenesis inhibitors like bevacizumab target vascular endothelial growth factor (VEGF) to slow tumor growth and metastasis.
The study found that PSA screening can reduce prostate cancer deaths by 20%, saving one life for every 1,408 men screened. The European Association of Urology's largest prostate cancer screening study provides robust evidence for the effectiveness of screening on prostate cancer mortality.
The European Association of Urology has released new clinical guidelines for kidney cancer treatment, emphasizing the use of targeted agents and nephron-sparing surgery. The guidelines recommend first-line therapies for low- and intermediate-risk patients, as well as second-line options for high-risk patients.
Researchers at the University of Michigan have identified a potential new biomarker, sarcosine, that can distinguish between aggressive and non-aggressive prostate cancers. Sarcosine levels in urine may help predict cancer aggressiveness and identify patients who need aggressive treatment.